Patrick Colin work email
- Valid
- Valid
- Valid
Patrick Colin personal email
More than 37 years of overall drug development experience. Experience in large ( Bristol Myers Squibb) and mid-size pharma ( Axcan Pharma) , as well as biotechs ( Purecell Technologies , GInova Pharma, Gicare Pharma ,Laurent Pharma and Verlyx Pharma) . Experience as well in the starting up of new firms, such as GInova Pharma Inc., Gicare Pharma inc. Giiant Pharma and Laurent Pharmaceuticals. Experience in BD of CRO services for CEE region in Europe. Experience in international Drug Development ConsultinExpertise in gastroenterology, hepatology, and cystic fibrosis. Experience also is other TAs, including but not limited to: cardiology, metabolic diseases, psychiatry, infectious diseases, oncology, women's health, dermatology , and biosimilar drugs development. Additional experience in clinical research conducted in developing countries (Dominican Republic and Peru).Has managed R & D teams (N: 43) responsible for 15 market approvals (following NDA, NDS, SNDA, SNDS, MA, PMA and Class 3 Medical Devices regulatory filings)People management: was responsible for a 43 people R & D group at Axcan. People oriented and team focused. Co-founder of GInova Pharma ( GI focused biotech). Prepared all development plans ( 3 NCEs) and actively participated to the financing round ( $ 15 M raised vs $ 20 M goal).Co-founder and Chief Development Officer of Gicare Pharma, a newly created GI focused biotech company. Gicare Pharma currently develops orally administered alternatives to IV sedation used in patients undergoing colonoscopy. Also co-founder of Laurent Pharma, a biotech developing drugs for the treatment of Cystic Fibrosis and COVID-19. Since 2024, VP, Clinical Development at Angany Inc, a biopharmaceutical company specialized in clinical allergy.Excellent medico-marketing skills. Speaks French and English fluently, and basic Spanish.
-
Vice PrésidentAngany Mar 2022 - PresentQuébec, Québec, Ca -
PresidentPatrick Colin Consultant Inc. Sep 2007 - PresentPCC Inc. is a Montreal based consulting firm specialized in drug development, from preclinical to Phase IV clinical. PCC inc. focuses on the strategic aspects of overall drug development programs.Drug development services offered in more than 10 Therapeutic Areas, including Gastroenterology, Cardiology, Metabolic Diseases, Oncology, Vaccines, etc...Strong expertise in GI-liver disease drug development. Experience in conducting international Phase 2 and 3 trials. Experience in clinical research in Eastern Europe, as well as developing countries such as Peru and Dominican Republic.Expertise in Clinical Pharmacology (Phase I SAD and MAD studies, PK, Biosimilar PK profiling, Bioequivalence, etc...)Provides privileged access to a large international Clinical Investigators-KOLs Network, including Poland and other Central and Eastern Europe countries.
-
Chief Development Advisor; Co-FounderLaurent Pharma Inc. Sep 2013 - PresentLaurent Pharma develops an innovative form of fenretinide (LAU-7b), a synthetic retinoid which corrects lipidomic imbalance in Cystic Fibrosis(CF) patients and favours inflammation resolution. This technology originates from McGill University and has been first evaluated in a Phase Ib clinical study. The company is currently conducting a large, international Phase 2 adult CF clinical trial (APPLAUD). Laurent also initiated a Phase 2 study in hospitalized COVID-19 patients, in light of the antiviral (host oriented) and anti-inflammatory properties of LAU-7b.
-
Chief Clinical OfficerGiiant Pharma Inc. Jan 2021 - Dec 2022Montreal, Quebec, CaGiiant Pharma is a new, Montreal based, gastroenterology(GI)-focused company with a gut-restricted, colon-specific PDE4 inhibitor prodrug as lead program, to treat and manage inflammatory bowel diseases (IBD). The Company is also creating a Drug Hunting Club to identify and acquire GI-liver focused assets in order to build a strong franchise in Precision Therapeutics. -
Chief Development OfficerVerlyx Pharma Inc. Mar 2015 - Jan 2018Verlyx Pharma was a Montreal, Canada, based clinical stage biotech specialized in the development of innovative products designed to treat inflammatory liver diseases such as Non Alcoholic Steatohepatitis ( NASH) , Acute Alcoholic Hepatitis ) AAH) and other prevalent hepatic disorders.
-
Chief Development Officer, Co-FounderGicare Pharma Inc. Jul 2011 - Feb 2015Montreal, Quebec, CaGicare Pharma was a clinical stage Canadian biopharmaceutical firm specialized in the development of innovative, orally administered colonic analgesic drugs designed as an alternative to IV sedation for patients under going full colonoscopy. -
Chief Development Officer, Co-FounderGinova Pharma Jan 2008 - Feb 2010GInova was a new biotech founded by 7 former pharma executives ( 3 from Axcan, including myself...). We have been trying to close a Series A round of financing of $ 20 M CDN for the last 18 months. We managed to successfully secured $ 15 M so far ( Term Sheet established with 3 VCs). However, we had to terminate this project, because we could not our reach our $ 20 M objective. The current financial context is extremely challenging, and GInova is now trying to license out its 3 promissing technologies.GInova 's innovative drug technologies address unmet medical needs for Celiac Disease, Ulcerative Colitis , and Sedation for Colonoscopy. As the CDO of the company, I was responsible for all aspects of the drug development programs, from pre-clinical tox to Phase II clinical.
-
Vp , R & DAxcan Pharmaceuticals 1994 - 2006This position was responsible for all aspects of Axcan's GI and liver disease drug development programs, including preclinical (CMC and tox), as well as Phase I, II and III clinical development. During my 12 years at Axcan, our team managed to obtain 12 marketing approvals in Canada, USA and EU (NDAs, SNDAs, NDS, etc...)A strong collaboration was also established between R & D and other key departments, such as Marketing, BD and Medical Affairs.R & D efforts at Axcan led to the approval of 12 regulatory filings, between 1994 and 2007 ( NDAs, SNDAs, NDSs, SNDSs, MAs, PMAs)I also actively participated to Axcan 's IPO in 1995, as well as Nasdaq listing in 1999. -
Manager, MetabolismBristol-Myers Squibb 1992 - 1994Lawrence Township, Nj, UsResponsible for Phase 2 clinical development, in the areas of dyslipidemia and peripheral vascular disease. -
Project LeaderBristol-Myers Squibb May 1989 - May 1992Lawrence Township, Nj, UsContributed to Phase 1-2 clinical development of pravastatin, a hypocholesterolemic drug.
-
Project ManagerSquibb Pharmaceuticals May 1987 - May 1989Responsible for biopharmaceutical development, therapeutic equivalence clinical studies, and bioanalytical development.
Patrick Colin Skills
Patrick Colin Education Details
-
Université De MontréalPharmacy
Frequently Asked Questions about Patrick Colin
What company does Patrick Colin work for?
Patrick Colin works for Angany
What is Patrick Colin's role at the current company?
Patrick Colin's current role is President, Patrick Colin Consultant Inc..
What is Patrick Colin's email address?
Patrick Colin's email address is pc****@****tron.ca
What schools did Patrick Colin attend?
Patrick Colin attended Université De Montréal.
What are some of Patrick Colin's interests?
Patrick Colin has interest in Drug Development, Investors, Gastroenterology.
What skills is Patrick Colin known for?
Patrick Colin has skills like Clinical Development, Oncology, Biotechnology, Drug Development, Clinical Trials, Cro, Pharmaceutical Industry, Gastroenterology, Clinical Research, Regulatory Affairs, Therapeutic Areas, Infectious Diseases.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial